- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 239/48 - Deux atomes d'azote
Détention brevets de la classe C07D 239/48
Brevets de cette classe: 1077
Historique des publications depuis 10 ans
|
100
|
78
|
85
|
65
|
78
|
50
|
61
|
32
|
30
|
15
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Bristol-myers Squibb Company | 4751 |
35 |
| Signal Pharmaceuticals, LLC | 176 |
34 |
| Rigel Pharmaceuticals, Inc. | 507 |
27 |
| Boehringer Ingelheim International GmbH | 4493 |
20 |
| Novartis AG | 10251 |
18 |
| Merck Patent GmbH | 5729 |
16 |
| Janssen Sciences Ireland UC | 155 |
15 |
| Korea Research Institute of Chemical Technology | 1475 |
15 |
| Alexion Pharmaceuticals, Inc. | 648 |
14 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 1024 |
14 |
| Afferent Pharmaceuticals, Inc. | 24 |
12 |
| Celgene Avilomics Research, Inc. | 31 |
12 |
| Takeda Pharmaceutical Company Limited | 2710 |
11 |
| Dana-Farber Cancer Institute, Inc. | 2665 |
11 |
| Portola Pharmaceuticals, Inc. | 82 |
11 |
| Corteva Agriscience LLC | 2640 |
11 |
| Deciphera Pharmaceuticals, LLC | 266 |
10 |
| Roche Palo Alto LLC | 64 |
10 |
| Genentech, Inc. | 4110 |
9 |
| AstraZeneca AB | 2819 |
9 |
| Autres propriétaires | 763 |